AXT Plummets 16.56% as $350M Volume Ranks 385th in U.S. Equities Amid Analyst Optimism and Downgrades

Market Snapshot

AXT (AXTI) fell 16.56% on March 6, 2026, marking one of its most volatile trading days in recent months. The stock’s trading volume surged by 42.38% to $350 million, ranking it 385th in volume among U.S. equities. Despite the sharp decline, the stock remains underpinned by analyst optimism, with an average price target of $41.14—representing a 6.03% potential upside from its previous close of $38.80. However, the recent drop contrasts with earlier gains in early 2026, including a 12.45% rally in October 2025 following better-than-expected Q3 2025 results.

Key Drivers

Analyst Sentiment and Price Targets

Analyst coverage for AXTI remains divided, with 76.92% of ratings favoring a “Buy” and 23.08% recommending a “Hold.” The latest price targets, as of February 20, 2026, range from $21 (B.Riley) to $29 (Craig-Hallum), reflecting cautious optimism about the company’s long-term prospects. However, recent downgrades, including Needham’s shift to a “Hold” on January 20 and B.Riley’s reduction of its target to $18, highlight growing uncertainty. The average time for price targets to materialize is 474 days, suggesting analysts expect gradual realization of value.

Earnings and Operational Challenges

AXT’s Q4 2025 earnings report, released on February 19, 2026, revealed mixed results. Revenue fell to $23 million in the quarter, down from $28 million in Q3 2025 and $25.1 million in Q4 2024, driven by reduced InP (Indium Phosphide) sales due to limited Chinese export permits. Gross margins also declined to 20.9% from 22.3% in the prior quarter. While the company’s full-year 2025 revenue of $88.3 million marked a 11% decline from 2024, management emphasized a $49 million backlog and plans to double InP production capacity. These factors underscore both near-term challenges and long-term growth potential in AI and optical connectivity markets.

Export Permit Constraints and Market Position

The primary drag on AXT’s performance remains its dependence on Chinese export permits for InP materials. InP revenue fell to $8 million in Q4 2025 from $13 million previously, a 38% drop that analysts attribute to regulatory delays. B.Riley noted the stock is likely to remain range-bound until clarity on permits emerges. Meanwhile, Wedbush’s raised price target of $28—based on a 30x 2027 earnings multiple—signals confidence in AXT’s ability to capitalize on InP’s high-growth trajectory, despite its low-margin profile.

Valuation and Growth Projections

Analysts’ divergent views reflect broader debates about AXT’s valuation. Wedbush’s aggressive multiple of 30x for 2027 earnings, though higher than typical for low-margin materials firms, is justified by expectations of rapid InP growth. Conversely, Riley’s neutral stance and lower price target of $21 highlight concerns about execution risks and margin compression. The company’s 40% market share in InP, coupled with CEO Dr. Morris Young’s emphasis on product quality, positions AXT to benefit from AI-driven demand. However, the stock’s 16.56% drop suggests investors remain wary of near-term headwinds, including supply chain bottlenecks and macroeconomic uncertainty.

Long-Term Outlook and Strategic Moves

Management’s guidance for Q4 2025 revenue of $27–30 million indicates confidence in stabilizing demand, despite export permit delays. The company’s focus on doubling InP capacity aligns with projected growth in AI and optical connectivity, sectors expected to drive long-term demand. Yet, the recent price targets and ratings adjustments suggest investors are factoring in a prolonged period of volatility. With Wedbush and Craig-Hallum maintaining “Buy” ratings and Riley adopting a cautious “Hold,” the stock’s trajectory will likely hinge on regulatory developments in China and AXT’s ability to execute its expansion plans.

Conclusion

AXT’s sharp decline on March 6, 2026, reflects a combination of near-term operational challenges, regulatory uncertainties, and mixed analyst sentiment. While the company’s strategic investments in InP and its strong backlog offer upside potential, the path to achieving analyst price targets remains clouded by export permit issues and margin pressures. Investors will need to balance optimism about long-term growth with caution regarding short-term risks, particularly in a market where regulatory and macroeconomic factors play a decisive role.